http://www.clinicaltrials.gov/
Rheumatology Division Clinical Trials: Main Page Penn Rheumatology The Division of Rheumatology at Penn Medicine is ranked highest in the Philadelphia region by U.S. News & World Report. National Fibromyalgia Association: Listing of Current Clinical T Clinical Trials Welcome to the National Fibromyalgia Association Clinical Trials Resource Center, presented in partnership with CenterWatch, the leading publisher of information on clinical research for patients and their advocates and healthcare professionals. Please click on the links below to learn more about clinical research and new medical therapies for treating fibromyalgia and related conditions. About Clinical Research This section provides background information about the clinical trials process and what to expect when you volunteer to participate in a clinical trial. Here, you'll find answers to frequently asked questions about clinical trials and also suggestions for where to find more information. Listing of Fibromyalgia Trials This is a listing of U.S. and international clinical trials actively recruiting patients for fibromyalgia.
Rheumatology Clinical Trails Penn Rheumatology The Division of Rheumatology at Penn Medicine is ranked highest in the Philadelphia region by U.S. News & World Report. Penn rheumatologists are known nationally and internationally for their clinical expertise and research scholarship. Go Clinical Trials - Be notified about a clinical trial in your Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials. What is a clinical trial?
Tai Chi Mind-Body Therapy for Fibromyalgia - Full Text View - Cl Primary Outcome Measures: Fibromyalgia Impact Questionnaire score [ Time Frame: wks 12 and 24 ] [ Designated as safety issue: No ] Secondary Outcome Measures: Tender Point Count, Fibromyalgia Intensity Score, Physicians' Assessments of Fibromyalgia Severity, Sleep Quality, Depression Index, Physical Performance, Self-Efficacy and Health Related Quality of Life [ Time Frame: Wks 12 and 24 ] [ Designated as safety issue: No ] Fibromyalgia (FM) is a common, complex chronic condition marked by diffuse musculoskeletal pain, fatigue, functional impairment, disability, and psychological distress that affects 6-10 million people in the United States (US). There are currently no satisfactory pharmacological or non-pharmacological treatments for FM. New cost-effective strategies that reduce musculoskeletal pain and improve emotional and physical functioning as well as quality of life in people with FM are urgently needed.
A Pilot Study of TMS Effects on Pain and Depression in Patients In this pilot study, the PI proposes to include 20 African American participants with Fibromyalgia to explore the effect of r TMS on pain and depressive symptoms. The focus on African Americans is due to the mandate from the funding source (internal), as well as possible higher prevalence of FM in AA women. If recruitment is slow, the PI proposes to open up the study to other groups. Tailored Cognitive-Behavioral Therapy for Fibromyalgia Patients Primary Outcome Measures: pain disability fatigue psychological distress at post treatment and 6 month follow-up Secondary Outcome Measures: passive coping illness cognitions social support at post treatment and 6 month follow-up The fibromyalgia syndrome is a chronic condition with widespread pain that poses a great challenge for patients, rheumatologists and society because of the lack of optimal treatment options. There is extensive evidence that, in comparison with patients with rheumatoid arthritis, fibromyalgia patients report higher levels of functional disability, pain, fatigue, and lower levels of quality of life.
HRV Biofeedback in Fibromyalgia - Full Text View - ClinicalTrial A growing body of evidence suggests that the symptoms of many fibromyalgia syndrome (FMS) sufferers might be the result of an imbalance in one of the major stress response systems, the autonomic nervous system. Thus respiratory sinus arrhythmia (RSA) biofeedback, which has shown promise in other conditions associated with an autonomic nervous system imbalance, could be effective in FMS. With the aid of sensors and computers, biofeedback involves modifying and/or learning how to control normally involuntary processes like blood pressure, heart rate and the autonomic nervous system through relaxation and breathing. The goal of this study is to test the effectiveness of a 10-session RSA biofeedback treatment for the symptoms of fibromyalgia. Forty patients receiving the RSA biofeedback treatment will be compared to 40 patients receiving another form of biofeedback thought to be minimally helpful (control group).
Neurotropin to Treat Fibromyalgia - Full Text View - ClinicalTri This study will examine the safety and effectiveness of the experimental drug, neurotropin, for preventing or easing pain associated with fibromyalgia. A disorder that primarily affects women, fibromyalgia causes widespread aching and stiffness in muscles. Neurotropin has been used in Japan for many years to treat various chronic painful conditions, including fibromyalgia. Eszopiclone in the Treatment of Insomnia and Fibromyalgia - Full Primary Outcome Measures: Total sleep time (TST) as recorded in patient diaries [ Time Frame: week 12 ] [ Designated as safety issue: No ] Secondary Outcome Measures: Wake time after sleep onset (WASO) [ Time Frame: week 12 ] [ Designated as safety issue: No ] Sleep quality [ Time Frame: week 12 ] [ Designated as safety issue: No ] Clinician-rated overall severity of fibromyalgia [ Time Frame: week 12 ] [ Designated as safety issue: No ] Fibromyalgia Impact Questionnaire [ Time Frame: week 12 ] [ Designated as safety issue: No ] Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of most theories.
Exercise-Based Motivational Interviewing for Fibromyalgia - Full Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. Drug therapy for FMS is largely symptomatic as there is not yet a complete understanding of the pathogenesis of the disease. In the past 17 years, supervised aerobic exercise has emerged as an important treatment modality to improve pain, aerobic capacity, function, and well-being. Individuals who are able to adhere to exercise almost always maintain the symptomatic benefits of exercise. Unfortunately, the rate of exercise adherence six months after the completion of a well-structured supervised exercise program is disappointingly low.
Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults Primary Outcome Measures: Ambulatory Pain (Higher Values Indicate Greater Pain) [ Time Frame: Baseline and after 12-weeks ] [ Designated as safety issue: No ]0 to 100 pain rating, higher numbers indicate greater pain Ambulatory Fatigue, Higher Values Indicate Greater Fatigue [ Time Frame: Baseline and after 12-weeks ] [ Designated as safety issue: No ]0-100 fatigue ratings, higher scores indicative of greater levels of fatigue Secondary Outcome Measures: Number of Tender Points on the Body [ Time Frame: Baseline and after 12-weeks ] [ Designated as safety issue: No ]Number of tender points on physical examination (maximum number is 18) Functional Capacity (Higher Scores Indicative of Poorer Functioning) [ Time Frame: Baseline and after 12-weeks ] [ Designated as safety issue: No ]Fibromyalgia Impact Questionnaire (a higher total score indicates poorer functioning). The range of possible scores is 0 to 100 This study will last 12 weeks.
Benefits of Tanning in Fibromyalgia Patients - Full Text View - Primary Outcome Measures: A 30% improvement in reported pain will be considered a treatment "success." As a secondary outcome, we will compare post-treatment pain scores between the UV and non-UV exposures given on the first day the dose is given (A vs. B in table 4).